Laval - Neurochem Inc.'s Independent Safety Review Board (ISRB) has issued a recommendation to continue the company's North American Phase III clinical trial for Alzhemed for the treatment of Alzheimer's disease (AD). The recommendation was based on their recent review of the safety data from 562 patients who have been monitored in the trial for at least 12 weeks so far. After reviewing the safety information, the ISRB concluded that there were no significant safety concerns to report in the study and that the trial should continue as planned.
Alzhemed is an orally administered, small organic molecule that has been specifically designed to modify the course of AD through its …
No comments:
Post a Comment